VOO vs XBI
Vanguard S&P 500 ETF vs SPDR S&P Biotech ETF
- • VOO has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • VOO pays a higher dividend yield (1.08%).
Side-by-side metrics
| Metric | VOO | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.08% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $1.60T | $8.30B |
YTD return | 7.92% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.00 | 1.09 |
P/E ratio | 29.04 | — |
Last price | $672.54 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VOO top holdings
| NVDA | NVIDIA Corp | 7.58% |
| AAPL | Apple Inc | 6.67% |
| MSFT | Microsoft Corp | 4.92% |
| AMZN | Amazon.com Inc | 3.64% |
| GOOGL | Alphabet Inc Class A | 3.00% |
| AVGO | Broadcom Inc | 2.63% |
| GOOG | Alphabet Inc Class C | 2.40% |
| META | Meta Platforms Inc Class A | 2.24% |
| TSLA | Tesla Inc | 1.87% |
| BRK-B | Berkshire Hathaway Inc Class B | 1.57% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VOO
VOO (Vanguard S&P 500 ETF) is Tracks the S&P 500 index of 500 large US companies. Managed by Vanguard, the fund carries $1.6T in assets under management, an expense ratio of 0.03%, a dividend yield of 1.08%. Its largest holding is NVIDIA Corp (NVDA), which represents 7.6% of the portfolio. Real Estate is the fund's largest sector exposure at 1.9%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.